Looming Velcade freefall shows why Takeda paid big for Shire

14th May 2018 Uncategorised 0

The multiple myeloma blockbuster Velcade has been Takeda’s cash cow for years, but those sales are starting to dry up, with a more than 30% drop expected this year, executives said in the company’s year-end earnings release. The Shire buyout will fill that gap—and far more.

More: Looming Velcade freefall shows why Takeda paid big for Shire
Source: fierce